AllianceBernstein’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

AllianceBernstein’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,280	Closed	-$63K	–	3406
2022 Q1	$63K	Buy	5,280 +20	+0.4%	+$358	﹤0.01%	3157
2021 Q4	$171K	Sell	5,260 -330	-6%	-$13.4K	﹤0.01%	3114
2021 Q3	$250K	Hold	5,590	–	–	﹤0.01%	3018
2021 Q2	$305K	Buy	5,590 +1,980	+55%	+$117K	﹤0.01%	3002
2021 Q1	$270K	Sell	3,610 -800	-18%	-$83.1K	﹤0.01%	2948
2020 Q4	$478K	Sell	4,410 -510	-10%	-$46.5K	﹤0.01%	2619
2020 Q3	$435K	Hold	4,920	–	–	﹤0.01%	2593
2020 Q2	$524K	Buy	4,920 +960	+24%	+$86.2K	﹤0.01%	2580
2020 Q1	$235K	Buy	3,960 +910	+30%	+$61.7K	﹤0.01%	2730
2019 Q4	$211K	Buy	3,050 +140	+5%	+$8.49K	﹤0.01%	2905
2019 Q3	$302K	Buy	2,910 +840	+41%	+$79.3K	﹤0.01%	2801
2019 Q2	$192K	Buy	2,070 +470	+29%	+$32.7K	﹤0.01%	2981
2019 Q1	$146K	Buy	1,600 +350	+28%	+$24.4K	﹤0.01%	2967
2018 Q4	$70K	Hold	1,250	–	–	﹤0.01%	3029
2018 Q3	$149K	Buy	1,250 +90	+8%	+$10.4K	﹤0.01%	3035
2018 Q2	$118K	Buy	+1,160	New	+$144K	﹤0.01%	3038

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein's SYRS Position: Q2 2022 in Review

AllianceBernstein sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 5,280 shares — an estimated $63K sold.

AllianceBernstein first reported a position in SYRS in Q2 2018 and held it in 16 quarters. The position peaked at $524K in Q2 2020. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

AllianceBernstein reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
AllianceBernstein sold 5,280 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $63K.
AllianceBernstein first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 16 quarters.
AllianceBernstein's Syros Pharmaceuticals, Inc. Common Stock position peaked at $524K in Q2 2020.
67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.